Mark Verrill, MA, MB, BChir, FRCP from The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK speaks about the process of developing a biosimilar. Biosimilars are developed through the reverse engineering of an originator drug; however, the finished agent is not identical to the originator. Therefore, the biosimilar has to be extensively tested using different analytical assays to ensure that it is chemically indistinguishable from the originator product. The safety legislations ensure that clinicians also monitor the effect after the biosimilar has been released into the market to certify that patient outcomes are not different. This interview was recorded at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates